Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
streptococcus pneumoniae type 2 capsular polysaccharide antigen
- Development stage
- Approved
- Lead developer
- Merck
- Modality
- Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Subcutaneous
01
Overview
Streptococcus pneumoniae type 2 capsular polysaccharide antigen is a highly purified bacterial carbohydrate derived from the capsule of Streptococcus pneumoniae serotype 2. It is used as an active immunizing agent in vaccines to induce immunity against invasive pneumococcal diseases, such as pneumonia and bacteremia, caused by S. pneumoniae serotype 2. The mechanism of action involves stimulating the immune system to produce antibodies specific to the serotype 2 capsule, thereby providing protection against infection by this strain. This antigen is included in multivalent pneumococcal vaccines like Pneumovax 23 (PPSV23), which contains purified capsular polysaccharides from multiple S. pneumoniae serotypes[7][5]. These vaccines are administered via intramuscular or subcutaneous injection for prophylaxis against pneumococcal disease.
- Brand names
- Pneumovax 23Pneumovax23Pneumovax-23
- Other names
- pneumococcal capsular polysaccharide type 2 vaccinestreptococcus pneumoniae type 2 capsular polysaccharide antigen
02
Targets
BCR (Immunoglobulin G B Cell Receptor)
Beyond the preview
Go deeper on streptococcus pneumoniae type 2 capsular polysaccharide antigen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on streptococcus pneumoniae type 2 capsular polysaccharide antigen.